Regulus Therapeutics (RGLS) Getting Somewhat Favorable News Coverage, Study Finds

Headlines about Regulus Therapeutics (NASDAQ:RGLS) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.2089669298025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

RGLS has been the subject of a number of research reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Saturday, September 16th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Finally, Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $2.60.

Shares of Regulus Therapeutics (RGLS) opened at $0.99 on Wednesday. Regulus Therapeutics has a twelve month low of $0.79 and a twelve month high of $2.75. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41.

COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/20/regulus-therapeutics-rgls-getting-somewhat-favorable-news-coverage-study-finds.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit